Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Achieves Second Milestone in GSK Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Cellzome said today that it has hit a second milestone in its ongoing epigentics collaboration with GlaxoSmithKline.

The firm did not disclose the amount of the payment, but said that it comes only two months after the firm achieved a first milestone in the collaboration.

As GenomeWeb Daily News reported in early 2010, GSK paid €33 million ($45 million) up front for exclusive access to Cellzome's Episphere for epigenetic research on immunoinflammatory disease. Cellzome could be eligible for milestone payments of over €475 million, the firms said at the time.

"Achieving the second milestone in this collaboration in less than a year after its start demonstrates how well our technology is suited to address drug discovery for epigenetic targets," Cellzome CEO Tim Edwards said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.